Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-toxicity Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Hematological Malignancies
NCT00841724Phase 2Completed
- Sponsor
- CHU de Nantes
- Start
- Jan 2009
- Primary completion
- Jan 2012
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fludarabine, busulfan and antithymocyte globulin rabbit in hematological malignancy, sponsored by CHU de Nantes. Primary endpoint: Overall Mortality Rate at 12 months. Started Jan 2009; status: completed.
02
Drugs
fludarabinebusulfanantithymocyte globulin rabbit
03
Conditions
hematological malignancy
Beyond the preview
Go deeper on NCT00841724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00841724.